Scholarlink

This was a patient with melanoma that developed optic neuritis 11 days after second cycle of pembrolizumab treatment. Patient improved with intravenous steroid and withholding pembrolizumab, although vision did not return to baseline post treatment, patient’s visual field and optic disc edema improved. The decision was made not to rechallenge with pembrolizumab. Patient is still undergoing different cancer treatment and was discharged to follow-up with local ophthalmologist.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Optic Neuritis Post Immune Checkpoint Inhibitor Therapy

  • 章节

  • 发表日期：

    2025年

查看全文
  • May Ameri,
  • Andrew Whyte,
  • Nagham Al-Zubidi

摘要

This was a patient with melanoma that developed optic neuritis 11 days after second cycle of pembrolizumab treatment. Patient improved with intravenous steroid and withholding pembrolizumab, although vision did not return to baseline post treatment, patient’s visual field and optic disc edema improved. The decision was made not to rechallenge with pembrolizumab. Patient is still undergoing different cancer treatment and was discharged to follow-up with local ophthalmologist.